ReviewInternational journal of cardiology. Heart & vasculature2022
A review of pathophysiological mechanism, diagnosis, and treatment of thrombosis risk associated with COVID-19 infection.
Review in International journal of cardiology. Heart & vasculature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07476404 (Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch (HES) Fluid Therapy: A Retrospective Cohort Study
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- The association between mortality due to COVID-19 and coagulative parameters: a systematic review and meta-analysis study.BMC infectious diseases · 2024Pooled it
- Recent highlights from theInternational journal of cardiology. Heart & vasculature · 2025Article
- Perioperative Coronavirus Disease 2019 Infection and Its Impact on Postoperative Outcomes: Pulmonary Complications and Mortality Based on Korean National Health Insurance Data.Journal of personalized medicine · 2025Article
- Thrombin receptor PAR4 cross-activates the tyrosine kinase c-met in atrial cardiomyocytes.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Coagulopathy and adverse outcomes in hospitalized patients with COVID-19: results from the NOR-Solidarity trial.Research and practice in thrombosis and haemostasis · 2024Article
- Recent highlights on specific aspects of oral anticoagulation in difficult clinical scenarios from theInternational journal of cardiology. Heart & vasculature · 2023Article
- Recent highlights from theInternational journal of cardiology. Heart & vasculature · 2023Article
- A U-shaped protection of altitude against mortality and infection of COVID-19 in Peru: an ecological study.BMC public health · 2023Article
- Recent highlights on myocarditis, cardiovascular complications of COVID-19, and cardiomyopathies from the International Journal of Cardiology: Heart & Vasculature.International journal of cardiology. Heart & vasculature · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe coronavirus (COVID-19) infection has been reportedly associated with a high risk of thromboembolism. Developing macrovascular thrombotic complications, including myocardial injury/infarction, venous thromboembolism, and stroke have been observed in one-third of severe COVID-19 hospitalized patients, leading to an increase in mortality and morbidity. The diagnosis of COVID-19 associated coagulopathy may be challenging because there are close similarities between pulmonary embolism and severe COVID-19 disease. Therefore, a critical step in improving the clinical outcome of patients with hospitalized COVID-19 is the recognition of coagulation abnormalities and the identification of patients with poor prognoses, prophylactic guidance, or antithrombotic therapy. Prescribing anticoagulants in all patients hospitalized with COVID-19 and 2-6 weeks post-hospital discharge in the absence of contraindications is recommended by most consensus documents published on behalf of professional societies. However, a decision on some variable factors such as intensity and duration of anticoagulation may be made based on an individual case and needs future randomized trial studies. Regarding little information on this subject, this study aims to review how inflammation and thrombosis are related to COVID-19 patients, discuss the types of thrombosis in these patients, and summarize the diagnosis and treatment of thrombosis in COVID19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.